GRTS Gritstone bio Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: GRTS

Price (delayed)

$1.32

Market cap

$125.85M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.24

Enterprise value

$190.37M

Gritstone bio, Inc., a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases. Gritstone develops its products by leveraging two key pillars—first, ...

Highlights
The EPS is up by 11% year-on-year
Gritstone bio's debt has surged by 125% YoY
The equity has declined by 46% year-on-year and by 32% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://gritstonebio.com
Peers: OMGA

Key stats

What are the main financial stats of GRTS
Market
Shares outstanding
95.34M
Market cap
$125.85M
Enterprise value
$190.37M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.66
Price to sales (P/S)
14.89
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
18.62
Earnings
Revenue
$10.23M
EBIT
-$135.46M
EBITDA
-$115.48M
Free cash flow
-$138.38M
Per share
EPS
-$1.24
Free cash flow per share
-$1.2
Book value per share
$0.79
Revenue per share
$0.09
TBVPS
$1.62
Balance sheet
Total assets
$187.22M
Total liabilities
$113.24M
Debt
$95.3M
Equity
$73.98M
Working capital
$67.44M
Liquidity
Debt to equity
1.29
Current ratio
3.88
Quick ratio
3.64
Net debt/EBITDA
-0.56
Margins
EBITDA margin
-1,129.4%
Gross margin
100%
Net margin
-1,359%
Operating margin
-1,379.9%
Efficiency
Return on assets
-64.6%
Return on equity
-112.2%
Return on invested capital
-63.6%
Return on capital employed
-82.7%
Return on sales
-1,324.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

GRTS stock price

How has the Gritstone bio stock price performed over time
Intraday
1.54%
1 week
0%
1 month
-30.16%
1 year
-54.79%
YTD
-61.74%
QTD
-23.26%

Financial performance

How have Gritstone bio's revenue and profit performed over time
Revenue
$10.23M
Gross profit
$10.23M
Operating income
-$141.1M
Net income
-$138.96M
Gross margin
100%
Net margin
-1,359%
The company's operating margin has shrunk by 119% YoY and by 22% QoQ
Gritstone bio's net margin has shrunk by 116% YoY and by 22% QoQ
The revenue has contracted by 45% YoY and by 12% from the previous quarter
GRTS's gross profit is down by 45% YoY and by 12% QoQ

Growth

What is Gritstone bio's growth rate over time

Valuation

What is Gritstone bio stock price valuation
P/E
N/A
P/B
1.66
P/S
14.89
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
18.62
The EPS is up by 11% year-on-year
The equity has declined by 46% year-on-year and by 32% since the previous quarter
GRTS's P/B is 21% below its 5-year quarterly average of 2.1 and 8% below its last 4 quarters average of 1.8
The stock's price to sales (P/S) is 66% less than its 5-year quarterly average of 44.1 and 21% less than its last 4 quarters average of 18.8
The revenue has contracted by 45% YoY and by 12% from the previous quarter

Efficiency

How efficient is Gritstone bio business performance
The return on sales has dropped by 111% year-on-year and by 21% since the previous quarter
The ROE has dropped by 67% year-on-year and by 20% since the previous quarter
Gritstone bio's ROA has decreased by 29% YoY and by 9% from the previous quarter
The ROIC is up by 20% year-on-year and by 4.2% since the previous quarter

Dividends

What is GRTS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for GRTS.

Financial health

How did Gritstone bio financials performed over time
The company's total assets is 65% higher than its total liabilities
The company's total liabilities has surged by 66% YoY
GRTS's quick ratio is down by 31% since the previous quarter and by 20% year-on-year
Gritstone bio's debt is 29% higher than its equity
Gritstone bio's debt has surged by 125% YoY
Gritstone bio's debt to equity has increased by 48% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.